Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | METAP1 | P53582 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29609730 | 1.00 | MAPT (0.44) | MAPTRAB9AKDM4ENPC1METAP1 | |
| SCHEMBL26350335 | 0.80 | PDE10A (0.40) | MAPTRAB9AKDM4ENPC1NPSR1 | |
| SCHEMBL16387910 | 0.78 | PDE10A (0.50) | MAPTRAB9AKDM4ENPC1METAP1 | |
| SCHEMBL30703605 | 0.77 | NISCH (0.37) | MAPTRAB9AKDM4ENPC1ALDH1A1 | |
| SCHEMBL29132841 | 0.77 | NISCH (0.37) | MAPTRAB9AKDM4ENPC1ALDH1A1 | |
| SCHEMBL5242265 | 0.76 | KMT2A (0.49) | MAPTALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL3575559 | 0.76 | MEN1 (0.53) | MAPTRAB9AKDM4ENPC1ALDH1A1 | |
| SCHEMBL3576610 | 0.75 | MEN1 (0.43) | MAPTRAB9AKDM4ENPC1ALDH1A1 | |
| SCHEMBL5264555 | 0.75 | ALDH1A1 (0.32) | MAPTRAB9AKDM4ENPC1NPSR1 | |
| SCHEMBL30502861 | 0.75 | KMT2A (0.47) | MAPTALDH1A1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326778-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-20240382470-A1 | Irak Inhibitor for Treating Cytokine Release-Related Conditions Associated With Infection by a Respiratory Virus | RIGEL PHARMACEUTICALS INC (US) | 2024-11-21 | — | — | US | disclosed |
| EP-4399208-A1 | IRAK INHIBITOR FOR TREATING CYTOKINE RELEASE-RELATED CONDITIONS ASSOCIATED WITH INFECTION BY A RESPIRATORY VIRUS | Rigel Pharmaceuticals, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| WO-2023038815-A1 | IRAK INHIBITOR FOR TREATING CYTOKINE RELEASE-RELATED CONDITIONS ASSOCIATED WITH INFECTION BY A RESPIRATORY VIRUS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
| US-20220289776-A1 | PYRAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2022-09-15 | — | — | US | disclosed |
| US-20220249475-A1 | COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME | RIGEL PHARMACEUTICALS, INC. (US) | 2022-08-11 | — | — | US | disclosed |
| CN-114698370-A | Compounds and methods for treating cytokine release syndrome | 里格尔药品股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| US-11370808-B2 | Pyrazole compounds and methods for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| EP-4009974-A1 | COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME | Rigel Pharmaceuticals, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |
| CN-113750094-A | Pyrazole compounds and methods of making and using the same | 里格尔药品股份有限公司 | 2021-12-07 | — | — | CN | disclosed |
| WO-2016172560-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| EP-1836188-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | Astex Therapeutics Limited (GB) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006070198-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | disclosed |
| EP-1080084-B1 | PROCESS FOR EPOXIDATION OF ARYL ALLYL ETHERS | DOW GLOBAL TECHNOLOGIES INC (US) | 2004-05-06 | — | — | EP | disclosed |
| CN-1303382-A | Epoxidation process for aryl allyl ethers | DOW CHEMICAL CO (US) | 2001-07-11 | — | — | CN | disclosed |
| EP-1080084-A2 | PROCESS FOR EPOXIDATION OF ARYL ALLYL ETHERS | THE DOW CHEMICAL COMPANY (US) | 2001-03-07 | — | — | EP | disclosed |
| US-6087513-A | REACTION OF ALLYL ARYL ETHER WITH HYDROGEN PEROXIDE IN THE PRESENCE OF TRANSITION METALS FOR OXIDATION | THE DOW CHEMICAL COMPANY (US) | 2000-07-11 | — | — | US | disclosed |
| WO-1999062894-A2 | PROCESS FOR EPOXIDATION OF ARYL ALLYL ETHERS | THE DOW CHEMICAL COMPANY (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | CDK1, CDK3, CDK13 | MAPT 447/4885RAB9A 3141/4885KDM4E 990/4885 |
| US-11370808-B2 | Pyrazole compounds and methods for making and using the compounds | IRAK3, IRAK1, IRAK2 | MAPT 2941/4885RAB9A 3188/4885KDM4E 1702/4885 |
| US-20250326778-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | IRAK3, IRAK1, IRAK2 | MAPT 2923/4885RAB9A 3229/4885KDM4E 1769/4885 |
| US-20220249475-A1 | COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME | IRAK1, IRAK3, IRAK2 | MAPT 3823/4885RAB9A 1559/4885KDM4E 989/4885 |
| US-20240382470-A1 | Irak Inhibitor for Treating Cytokine Release-Related Conditions Associated With Infection by a Respiratory Virus | IRAK1, IRAK4, IRAK2 | MAPT 2420/4885RAB9A 1685/4885KDM4E 487/4885 |
| US-20220289776-A1 | PYRAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS | IRAK3, IRAK1, IRAK2 | MAPT 2941/4885RAB9A 3188/4885KDM4E 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.